Department of Urology

Medicine & Life Sciences

1. Prostatectomy 100%
2. Prostatic Neoplasms 96%
3. Nephrectomy 81%
4. Lower Urinary Tract Symptoms 77%
5. Prostate 76%
6. Urinary Bladder 68%
7. Prostatic Hyperplasia 62%
8. Erectile Dysfunction 59%
9. Cystectomy 56%
10. Prostate-Specific Antigen 51%
11. Urinary Bladder Neoplasms 49%
12. Kidney 46%
13. Robotics 42%
14. Neoplasms 42%
15. Renal Cell Carcinoma 38%
16. Safety 37%
17. Multicenter Studies 36%
18. Recurrence 35%
19. Overactive Urinary Bladder 35%
20. Carcinoma 34%
21. Prostatitis 34%
22. Neoplasm Grading 27%
23. Therapeutics 26%
24. Urinary Tract 25%
25. Placebos 25%
26. Survival 25%
27. Nephroureterectomy 25%
28. udenafil 24%
29. Urodynamics 24%
30. Metabolic Syndrome 23%
31. Margins of Excision 22%
32. Pelvic Pain 22%
33. Transitional Cell Carcinoma 22%
34. Biopsy 22%
35. Interstitial Cystitis 22%
36. Retrospective Studies 19%
37. Watchful Waiting 19%
38. mirodenafil 19%
39. Type II Bone Morphogenetic Protein Receptors 18%
40. Urine 18%
41. Premature Ejaculation 18%
42. Tamsulosin 17%
43. Urinary Bladder Neck Obstruction 17%
44. Glomerular Filtration Rate 16%
45. Neoplasm Metastasis 16%
46. Chronic Pain 16%
47. Nomograms 16%
48. Serum 16%
49. Vulvodynia 16%
50. Cystitis 14%
51. Bone Morphogenetic Proteins 14%
52. Urination 14%
53. Cohort Studies 14%
54. Ureter 14%
55. Prospective Studies 14%
56. Urinary Tract Infections 14%
57. Antihypertensive Agents 14%
58. Urinary Incontinence 14%
59. Video-Assisted Surgery 13%
60. Lymph Nodes 13%
61. Solid-State Lasers 13%
62. Quality of Life 13%
63. Pelvic Floor 13%
64. Telomerase 13%
65. Recovery of Function 12%
66. Confidence Intervals 12%
67. Transforming Growth Factors 12%
68. Clinical Studies 12%
69. Ciprofloxacin 12%
70. Phosphodiesterase 5 Inhibitors 12%
71. Urology 12%
72. Living Donors 12%
73. Transurethral Resection of Prostate 12%
74. Odds Ratio 12%
75. Bone Morphogenetic Protein 6 12%
76. Systematic Reviews 11%
77. Lymph Node Excision 11%
78. Muscles 11%
79. Meta-Analysis 11%
80. Warm Ischemia 11%
81. alfuzosin 11%
82. Nocturia 11%
83. Urologists 10%
84. Controlled Clinical Trials 10%
85. C-Reactive Protein 10%
86. Clomipramine 10%
87. Bone Morphogenetic Protein Receptors 10%
88. Tissue Donors 10%
89. Ketoglutaric Acids 10%
90. Sexual Behavior 10%
91. Multivariate Analysis 10%
92. Incidence 10%
93. Tumor Burden 9%
94. Surgeons 9%
95. Testosterone 9%
96. Coitus 9%
97. Ejaculation 9%
98. Cell-Free Nucleic Acids 9%
99. Escherichia coli 9%
100. Sildenafil Citrate 9%